Literature DB >> 19597183

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Ryan A Wilcox1, Andrew L Feldman, David A Wada, Zhi-Zhang Yang, Nneka I Comfere, Haidong Dong, Eugene D Kwon, Anne J Novak, Svetomir N Markovic, Mark R Pittelkow, Thomas E Witzig, Stephen M Ansell.   

Abstract

Stromal elements present within the tumor microenvironment may suppress host immunity and promote the growth of malignant lymphocytes in B cell-derived non-Hodgkin lymphoma (NHL). In contrast, little is known about the microenvironment's role in T cell-derived NHL. B7-H1 (PD-L1, CD274), a member of the B7 family of costimulatory/co-inhibitory ligands expressed by both malignant cells and stromal cells within the tumor microenvironment, has emerged as an important immune modulator capable of suppressing host immunity. Therefore, B7-H1 expression and function were analyzed in cutaneous and peripheral T-cell NHL. B7-H1 was expressed by tumor cells, monocytes, and monocyte-derived cells within the tumor microenvironment in T-cell NHL and was found to inhibit T-cell proliferation and promote the induction of FoxP3(+) regulatory T cells. Collectively, the data presented provide the first evidence implicating B7-H1 in the suppression of host immunity in T-cell lymphoproliferative disorders and suggest that the targeting of B7-H1 may represent a novel therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597183      PMCID: PMC2744574          DOI: 10.1182/blood-2009-04-216671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).

Authors:  E C Vonderheid; R D Bigler; A Kotecha; C M Boselli; S R Lessin; M G Bernengo; M Polansky
Journal:  J Invest Dermatol       Date:  2001-09       Impact factor: 8.551

Review 2.  The new B7s: playing a pivotal role in tumor immunity.

Authors:  Dallas B Flies; Lieping Chen
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

3.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

4.  Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock.

Authors:  Thierry Fumeaux; Jérôme Pugin
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

5.  Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.

Authors:  A E Loercher; M A Nash; J J Kavanagh; C D Platsoucas; R S Freedman
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

7.  Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis.

Authors:  Akihiko Satoh; Toshihiko Miura; Kennichi Satoh; Atsushi Masamune; Tetsuya Yamagiwa; Yoshitaka Sakai; Kazuhiko Shibuya; Kazunori Takeda; Mitsuo Kaku; Tooru Shimosegawa
Journal:  Pancreas       Date:  2002-10       Impact factor: 3.327

Review 8.  Does the immune system see tumors as foreign or self?

Authors:  Drew Pardoll
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

10.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

View more
  79 in total

1.  Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Authors:  J A Yared; N Hardy; Z Singh; S Hajj; A Z Badros; M Kocoglu; S Yanovich; E A Sausville; C Ujjani; K Ruehle; C Goecke; M Landau; A P Rapoport
Journal:  Bone Marrow Transplant       Date:  2016-02-01       Impact factor: 5.483

Review 2.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

3.  Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Authors:  Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

4.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

5.  Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.

Authors:  Takeshi Sugio; Kohta Miyawaki; Koji Kato; Kensuke Sasaki; Kyohei Yamada; Javeed Iqbal; Toshihiro Miyamoto; Koichi Ohshima; Takahiro Maeda; Hiroaki Miyoshi; Koichi Akashi
Journal:  Blood Adv       Date:  2018-09-11

Review 6.  Cancer-associated myeloproliferation: old association, new therapeutic target.

Authors:  Ryan A Wilcox
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

7.  Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression.

Authors:  Huanbin Xu; Xiaolei Wang; Bapi Pahar; Terri Moroney-Rasmussen; Xavier Alvarez; Andrew A Lackner; Ronald S Veazey
Journal:  J Immunol       Date:  2010-11-08       Impact factor: 5.422

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 10.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.